ARTICLE | Company News

Actient, Columbia Laboratories sales and marketing update

April 25, 2011 7:00 AM UTC

Actient acquired U.S. rights to Columbia Laboratories' Striant testosterone buccal system for an undisclosed upfront cash payment. The mucoadhesive buccal tablets are approved for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone. Columbia is eligible for royalties. ...